Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

SciClone sets aside $2 million for ongoing FCPA probe

SciClone Pharmaceuticals Inc. said it has reserved $2 million for penalties related to an ongoing Foreign Corrupt Practices Act probe.

The California-based phrama said in its annual report last week that a settlement of that size was “probable.” But it didn’t not have any prediction about the exact fines that could be imposed or the timing of a resolution.

The DOJ and SEC are investigating  sales and marketing expenses at SciClone’s China subsidiary, NovaMed Pharmaceuticals (Shanghai) Co. Ltd.

SciClone received subpoenas from the SEC in late 2010 and again in late 2012. After an internal investigation, the company self-reported its findings to the feds in May 2011.

SciClone said it found a “lack of controls to ensure that third-party gifts, travel and entertainment expenses, and sponsorships of certain conferences and symposia complied with the law.”


Julie DiMauro is the executive editor of FCPA Blog and can be reached here.

Share this post


Comments are closed for this article!